Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2324 studies found for:    EGFR
Show Display Options
Rank Status Study
21 Completed Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
22 Recruiting Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
Condition: Advanced Stage Non Small Cell Lung Cancer
Interventions: Drug: Erlotinib 100mg qd;   Drug: Gefitinib 250mg qd
23 Completed Europe-Japan Diagnostic Study for EGFR Testing
Condition: EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
Intervention:
24 Completed Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions
Condition: Advanced Colorectal Cancer
Intervention: Drug: Cetuximab, irinotecan
25 Terminated A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
Condition: EGFR Positive Solid Tumors
Intervention: Drug: IMGN289
26 Completed Detecting EGFR T790M Mutations From Circulating Tumor Cells
Condition: Non Small Cell Lung Cancer
Intervention: Device: Circulating tumor cell chip
27 Not yet recruiting Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
Condition: Asymptomatic Brain Metastases of Non Small Cell Lung Cancer
Intervention: Drug: EGFR-TKI
28 Recruiting Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)
Condition: Stage IV EGFR Mutated NSCL With Brain Metastases
Interventions: Drug: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib;   Radiation: WBRT;   Radiation: HFSRS
29 Recruiting Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EGFR-TKIs;   Radiation: thoracic radiotherapy
30 Completed Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
Condition: Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
Intervention:
31 Recruiting Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study
Condition: EGFR Mutation Positive Non Small Cell Lung Cancer
Intervention:
32 Recruiting Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Conditions: Lung Neoplasms;   EGFR Gene Mutations
Intervention: Drug: Osimertinib
33 Not yet recruiting EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
Condition: Non-Small-Cell Lung Cancer
Interventions: Drug: EGFR-TKI;   Drug: Chemotherapy(pemetrexed/gemcitabine);   Drug: Chemotherapy(carboplatin)
34 Unknown  Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients
Condition: Metastatic Non-Small-Cell Lung Cancer
Intervention:
35 Recruiting PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Intervention:
36 Recruiting Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
Conditions: NSCLC;   EGFR Mutation
Intervention: Drug: Erlotinib
37 Recruiting TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Osimertinib;   Other: Pharmacological Study;   Drug: Sapanisertib
38 Completed Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention:
39 Unknown  A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status
Condition: NSCLC
Intervention: Other: EGFR mutation status in patients
40 Unknown  Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)
Condition: Nonsmall Cell Lung Cancer
Intervention: Drug: salvage iressa

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.